Acadia (ACAD) Q4 2025 earnings review
Surpassing $1B in Sales, But Distorted by Tax and IRA Accounting
Acadia wrapped up a milestone year by surpassing $1 billion in annual revenue, but the Q4 print is a maze of accounting adjustments. Top-line demand is strong: DAYBUE grew 13% YoY to $110 million, and NUPLAZID volume grew 13%. However, higher-than-expected IRA inflation cap invoices forced a $20 million retroactive charge, heavily distorting GAAP revenue. Meanwhile, a massive $250 million non-cash tax benefit artificially inflated Net Income to $274 million. Stripping out the noise, core Operating Income was just $17.4 million as SG&A spending surged to fund a 30% sales force expansion. FY26 guidance projects robust revenue growth, but investors must monitor the soaring costs and new European regulatory headwinds.
🐂 Bull Case
Stripping away the IRA rebate accounting, NUPLAZID generated $189 million in adjusted net sales (+17% YoY), driven by a 30% field force expansion. DAYBUE successfully rebounded to $110 million, showing stable quarter-over-quarter growth.
Management issued aggressive FY26 revenue guidance of $1.22B to $1.28B. This implies strong double-digit growth for both key franchises, signaling confidence that recent commercial investments are yielding returns.
🐻 Bear Case
Acadia received its first IRA inflation cap invoices, and they were higher than expected, forcing a $20 million retroactive adjustment. This signals that government price controls will increasingly pressure gross-to-net margins.
A concurrent update revealed the EMA's CHMP issued a negative trend vote on the European Marketing Authorization Application for trofinetide (DAYBUE), putting a major planned international growth driver at severe risk.
⚖️ Verdict: ⚪
Neutral. Commercial execution in the U.S. is commendable, and the top-line trajectory is clearly accelerating. However, the unexpected IRA margin hit, skyrocketing SG&A costs, and the major European regulatory setback limit the upside.
Key Themes
Inflation Reduction Act (IRA) Margin Shock
The realities of the IRA hit home this quarter. Acadia received its first inflation cap rebate invoices, which came in higher than projected. This necessitated a $20 million change in estimate for accruals dating back to FY22. Management pushed a 'Non-GAAP Adjusted Revenue' metric to reallocate this hit, but the underlying reality is that government pricing pressure is materially impacting NUPLAZID's realized revenue.
The 'Net Income' Illusion vs Soaring SG&A
Headline Net Income of $274 million for Q4 is wildly misleading, driven almost entirely by a $250 million non-cash tax benefit related to a valuation allowance reversal. Actual Operating Income was just $17.4 million. A key drag on profitability is accelerating Selling, General, and Administrative (SG&A) expenses, which jumped 20% YoY to $156 million to fund the 30% expansion of the NUPLAZID and DAYBUE field forces. FY26 guidance projects SG&A to climb even higher to $660-$700 million.
DAYBUE STIX Formulation Launch
DAYBUE unit sales grew 13% YoY in Q4, and the company is aiming to unlock the next wave of growth through innovation in delivery. DAYBUE STIX (trofinetide) for oral solution has shipped to its first patient, with a broader launch planned for early Q2 2026. This powder formulation could improve the patient experience, potentially addressing historical GI tolerability and persistency issues that have challenged the liquid formulation.
European DAYBUE Setback
Despite management heavily promoting the EU launch opportunity in prior quarters (estimating 9,000-12,000 patients), a concurrent PR reveals the EMA's CHMP delivered a negative trend vote on the Marketing Authorization Application for trofinetide. Acadia plans to request a re-examination, but this severely derisks the near-term international growth narrative and isolates the company's reliance on the U.S. market.
Remlifanserin (ACP-204) Remains the Primary Catalyst
With the prior failure of ACP-101 in Prader-Willi, the pipeline's value hinges squarely on remlifanserin (ACP-204). Management confirmed that the Phase 2 RADIANT study in Alzheimer’s disease psychosis remains on track for top-line results between August and October 2026. This represents the single most important binary catalyst for the stock over the next 12 months.
Other KPIs
Stable. Up from $756.0 million at the end of FY24. The strong cash position provides a solid buffer to absorb the planned SG&A and R&D spending increases in FY26 without needing dilutive capital raises.
Decelerating YoY. Down from $100.7 million in Q4 2024. However, the prior-year period included a one-time $28 million upfront payment to Saniona for ACP-711. Stripping that out, core clinical trial execution costs are rising.
Guidance
Accelerating. The midpoint of $1.25 billion represents roughly 17% growth over FY25's GAAP revenue of $1.07 billion. This indicates management's high confidence in the returns generated by the recent sales force expansion.
Accelerating. Implies ~14% growth at the midpoint over FY25's $680 million. The guide suggests the 30% increase in customer-facing representatives will successfully offset the growing headwinds from IRA inflation cap rebates.
Accelerating. Implies ~21% YoY growth at the midpoint over FY25's $391 million. This robust target likely assumes successful uptake of the new STIX formulation and deeper penetration into community physician settings.
Decelerating growth rate, but expanding in absolute dollars. The $680 million midpoint represents a 24% increase over FY25's $549 million. This aggressively high spend profile limits near-term operating leverage.
Key Questions
IRA Rebate Run-Rate
With the $20 million retroactive true-up for IRA inflation cap rebates, what should investors model as the normalized gross-to-net impact for NUPLAZID going forward into FY26?
European Contingency Plan
Following the negative trend vote from the CHMP for trofinetide, what is the probability of success for a re-examination, and how does this alter the timeline and capital allocation for the European commercial team?
DAYBUE STIX Expectations
Does the FY26 DAYBUE guidance of $460-$490 million assume the STIX formulation will meaningfully improve long-term patient persistency rates beyond the historical 50% plateau?
Path to Operating Leverage
With SG&A guided to grow by ~24% next year, outpacing top-line revenue growth of ~17%, when does the company expect to achieve sustained, unadjusted operating leverage?